Prostate Adenocarcinoma
249
57
102
85
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
65 trials with published results (26%)
Research Maturity
85 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.2%
28 terminated out of 249 trials
75.2%
-11.3% vs benchmark
7%
18 trials in Phase 3/4
76%
65 of 85 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 85 completed trials
Clinical Trials (249)
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer
Two-fraction HDR Monotherapy for Localized Prostate Cancer
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
High-Risk prostatE Cancer radiatiOn Versus surgERy
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring